Comparing Rhythm with the maker of cologuard, Exact Sciences, the latter is probably where Rhythm wants to be in a few years: ColoSTAT being a product already well established on the market and with a portfolio or pipeline of other products being commercialised. Worth emphasising that Rhythm has a market capitalisation of about A$270m and Exact Sciences has a market cap closer to A$20b. Even if we have to cope some dilution as the company grows, the potential gains are significant. For me, it all depends on study 7 (and not being taken over).
Ann: Rhythm Maintains Ongoing ISO13485 Certification, page-24
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 116320 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 347 | 2 |
View Market Depth
| Last trade - 09.23am 01/07/2024 (20 minute delay) ? |
| RHY (ASX) Chart |
Day chart unavailable